Effect of Tumor Necrosis Factor Alpha Inhibition on Bone Density and Turnover Markers in Patients with Rheumatoid Arthritis and Spondyloarthropathy

Seminars in Arthritis and Rheumatism

Volumn 39, Issue 2, 2009, Pages 116-122

  Barnabe, Cheryl ^a   Hanley, David A ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Anti tumor necrosis factor alpha; bone mineral density; bone turnover markers; osteoporosis; rheumatoid arthritis; spondyloarthropathy

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; ETANERCEPT; INFLIXIMAB; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; REGULATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; BONE DENSITY; BONE EROSION; BONE TURNOVER; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; HIP; HUMAN; LUMBAR SPINE; MEDLINE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; BONE RESORPTION; DATABASES, BIBLIOGRAPHIC; FEMALE; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOGENESIS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349454163     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.04.004     Document Type: Article

References (28)

1. Sinigaglia L., Varenna M., Girasole G., and Bianchi G. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 32 (2006) 631-658
2. Romas E., and Gillespie M.T. Inflammation-induced bone loss: can it be prevented?. Rheum Dis Clin North Am 32 (2006) 759-773
3. Henderson N.K., and Sambrook P.N. Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone. Curr Opin Rheumatol 8 (1996) 365-369
4. Rosen C.J. Postmenopausal osteoporosis. New Engl J Med 353 (2005) 595-603
5. Woolf A.D. An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 19 (2007) 370-375
6. Saag K.G., Shane E., Boonen S., Marin F., Donley D.W., Taylor K.A., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357 (2007) 2028-2039
7. Maricic M. New and emerging treatments for osteoporosis. Curr Opin Rheumatol 19 4 (2007) 364-369
8. Gartlehner G., Hansen R.A., Jonas B.L., Thieda P., and Lohr K.N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 33 (2006) 2398-2408
9. Maksymowych W.P., Inman R.D., Gladman D., Thomson G., Stone M., Karsh J., et al., The Spondyloarthritis Research Consortium of Canada (SPARCC). Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-α directed therapies in the treatment of spondyloarthritis. J Rheumatol 30 (2003) 1356-1363
10. Chopin F., Garnero P., le Henanff A., Debiais F., Daragon A., Roux C., et al. Long term effects of Infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis (2007) epub
11. Marotte H., Pallot-Prades B., Grange L., Gaudin P., Alexandre C., and Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 9 3 (2007) R61
12. Seriolo B., Paolino S., Sulli A., Ferretti V., and Cutolo M. Bone metabolism changes during anti-TNF-α therapy in patients with active rheumatoid arthritis. Ann NY Acad Sci 1069 (2006) 420-427
13. Vis M., Havaardsholm E.A., Haugeberg G., Uhlig T., Voskuyl A.E., van de Stadt R.J., et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 1495-1499
14. Lange U., Teichmann J., Muller-Ladner U., and Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatology 44 (2005) 1546-1548
15. Briot K., Garnero P., Le Henanff A., Dougados M., and Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment. Ann Rheum Dis 64 (2005) 1137-1140
16. Allali F., Breban M., Porcher R., Maillefert J.F., Dougados M., and Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α. Ann Rheum Dis 62 (2003) 347-349
17. Demis E., Roux C., Breban M., and Dougados M. Infliximab in spondyloarthropathy-influence on bone density. Clin Exp Rheumatol 20 6 Suppl 28 (2002) S185-S186
18. Gengenbacher M., Sebald H.-J., Villiger P.M., Hofstetter W., and Seitz M. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis (2007) Epub
19. Vis M., Wolbink G.J., Lodder M.C., Kostense P.J., van de Stadt R.J., de Koning M.H.M.T., et al. Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum 48 10 (2003) 2996-3000
20. Hermann J., Mueller T., Fahrleitner A., and Dimai H.P. Early onset and effective inhibition of bone resorption in patients with rheumatoid arthritis treated with the tumour necrosis factor alpha antibody infliximab. Clin Exp Rheum 21 (2003) 473-476
21. Torikai E., Kageyama Y., Takahashi M., Suzuki M., Ichikawa T., Nagafusa T., et al. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology 45 (2006) 761-764
22. Ziolkowska M., Kurowska M., Radzikowska A., Luszcykiewicz G., Wiland P., Dziewczopolski W., et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment. Arthritis Rheum 46 7 (2002) 1744-1753
23. Toussirot E., and Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol 19 4 (2007) 340-345
24. Saidenberg-Kermanac'h N., Corrado A., Lemeiter D., deVernejoul M.C., Boissier M.C., and Cohen-Solal M.E. TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35 5 (2004) 1200-1207
25. Visvanathan S., Marini J.C., Smolen J.S., St. Clair W.E., Pritchard C., Shergy W., et al. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol 34 (2007) 1465-1474
26. Kim T.-H., Stone M., Payne U., Zhang X., Ionescu M., Lobanok T., et al. Cartilage biomarkers in ankylosing spondylitis. relationship to clinical variables and treatment response. Arthritis Rheum 52 3 (2005) 885-891
27. Korczowska I., Hrycaj P., and Lacki J.K. [Change in biomarkers of osteoporosis in rheumatoid arthritis patients treated with infliximab]. Pol Arch Med Wewn 111 6 (2004) 673-678
28. Ostanek L., Pawlik A., Brzosko I., Vrzosko M., Sterna R., Drozdzik M., et al. The urinary excretion of pyridinoline and deoxypyridinoline during rheumatoid arthritis therapy with infliximab. Clin Rheumatol 23 (2003) 214-217